COYA

Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company founded in 2020 and headquartered in Houston, Texas. The company went public in December 2022 and focuses on developing innovative therapeutic treatments that harness the power of regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic diseases. Coya represents a relatively new entrant in the specialized field of immunotherapy, specifically targeting diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia through novel approaches involving cellular therapy and biologics.